Commonwealth Equity Services’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$12.7M Buy
16,385
+263
+2% +$201K 0.02% 763
2025
Q4
$12.4M Sell
16,122
-12
-0.1% -$8.15K 0.02% 784
2025
Q3
$9.07M Sell
16,134
-1,621
-9% -$917K 0.01% 971
2025
Q2
$9.32M Sell
17,755
-664
-4% -$371K 0.01% 957
2025
Q1
$11.7M Buy
18,419
+405
+2% +$279K 0.02% 780
2024
Q4
$12.8M Sell
18,014
-967
-5% -$812K 0.02% 705
2024
Q3
$20M Sell
18,981
-1,171
-6% -$1.3M 0.03% 519
2024
Q2
$21.2M Buy
20,152
+780
+4% +$756K 0.03% 480
2024
Q1
$18.6M Buy
19,372
+526
+3% +$500K 0.03% 516
2023
Q4
$16.6M Buy
18,846
+508
+3% +$418K 0.03% 521
2023
Q3
$15.1M Sell
18,338
-64
-0.3% -$50.3K 0.03% 516
2023
Q2
$13.2M Sell
18,402
-2,254
-11% -$1.74M 0.03% 571
2023
Q1
$17K Buy
20,656
+183
+0.9% +$138K 0.04% 451
2022
Q4
$14.8M Buy
20,473
+3,600
+21% +$2.66M 0.04% 480
2022
Q3
$11.6M Sell
16,873
-820
-5% -$516K 0.03% 518
2022
Q2
$10.5M Buy
17,693
+1,551
+10% +$1.01M 0.03% 564
2022
Q1
$11.3M Sell
16,142
-6,025
-27% -$3.81M 0.03% 574
2021
Q4
$14M Sell
22,167
-1,867
-8% -$1.15M 0.03% 480
2021
Q3
$14.5M Buy
24,034
+7,628
+46% +$4.74M 0.04% 435
2021
Q2
$9.16M Buy
16,406
+2,200
+15% +$1.11M 0.02% 591
2021
Q1
$6.72M Buy
14,206
+2,390
+20% +$1.16M 0.02% 652
2020
Q4
$5.71M Sell
11,816
-392
-3% -$212K 0.02% 667
2020
Q3
$6.83M Sell
12,208
-596
-5% -$361K 0.02% 552
2020
Q2
$7.99M Buy
12,804
+1,921
+18% +$1.09M 0.03% 478
2020
Q1
$5.31M Buy
10,883
+1,413
+15% +$583K 0.02% 530
2019
Q4
$3.56M Sell
9,470
-527
-5% -$177K 0.01% 748
2019
Q3
$2.77M Buy
9,997
+416
+4% +$123K 0.01% 808
2019
Q2
$3M Buy
9,581
+726
+8% +$242K 0.01% 763
2019
Q1
$3.64M Sell
8,855
-80
-0.9% -$32.9K 0.02% 666
2018
Q4
$3.34M Buy
8,935
+997
+13% +$365K 0.02% 635
2018
Q3
$3.21M Buy
7,938
+1,481
+23% +$564K 0.02% 691
2018
Q2
$2.23M Buy
6,457
+771
+14% +$241K 0.01% 849
2018
Q1
$1.96M Buy
5,686
+427
+8% +$149K 0.01% 876
2017
Q4
$1.98M Buy
5,259
+158
+3% +$64K 0.01% 860
2017
Q3
$2.28M Buy
5,101
+162
+3% +$77.1K 0.01% 743
2017
Q2
$2.43M Sell
4,939
-717
-13% -$314K 0.02% 684
2017
Q1
$2.19M Buy
5,656
+633
+13% +$235K 0.01% 699
2016
Q4
$1.84M Sell
5,023
-42
-0.8% -$16K 0.01% 737
2016
Q3
$2.04M Buy
5,065
+59
+1% +$23.7K 0.02% 675
2016
Q2
$1.75M Buy
5,006
+695
+16% +$268K 0.01% 710
2016
Q1
$1.55M Buy
4,311
+2
+0% +$824 0.01% 746
2015
Q4
$2.34M Buy
4,309
+39
+0.9% +$21.1K 0.02% 565
2015
Q3
$1.99M Sell
4,270
-8
-0.2% -$4.3K 0.02% 601
2015
Q2
$2.18M Sell
4,278
-529
-11% -$258K 0.02% 592
2015
Q1
$2.17M Sell
4,807
-734
-13% -$311K 0.02% 572
2014
Q4
$2.27M Buy
5,541
+1,422
+35% +$559K 0.03% 526
2014
Q3
$1.49M Buy
4,119
+125
+3% +$41.9K 0.02% 666
2014
Q2
$1.13M Sell
3,994
-961
-19% -$285K 0.01% 806
2014
Q1
$1.49M Buy
4,955
+763
+18% +$235K 0.02% 626
2013
Q4
$1.15M Buy
4,192
+213
+5% +$61.3K 0.02% 697
2013
Q3
$1.25M Buy
3,979
+847
+27% +$223K 0.02% 622
2013
Q2
$704K Buy
+3,132
New +$729K 0.01% 855

Other funds holding REGN

Commonwealth Equity Services's REGN Position: Q1 2026 in Review

Commonwealth Equity Services increased its Regeneron Pharmaceuticals (REGN) stake by 1.6% in Q1 2026, buying an estimated $201K and bringing the position to 16,385 shares worth $12.7M. The position accounts for 0.02% of the portfolio, ranked #763.

Commonwealth Equity Services first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $21.2M in Q2 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Commonwealth Equity Services held 16,385 shares of Regeneron Pharmaceuticals worth $12.7M as of Q1 2026.
  • Commonwealth Equity Services bought 263 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $201K.
  • Regeneron Pharmaceuticals made up 0.02% of Commonwealth Equity Services's portfolio in Q1 2026, its #763 holding.
  • Commonwealth Equity Services first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Commonwealth Equity Services's Regeneron Pharmaceuticals position peaked at $21.2M in Q2 2024.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Commonwealth Equity Services's 13F filing for Q1 2026, filed 27 Apr 2026.